诺华公司将从Synnovation购买乳腺癌药物SNV4818,价值高达30亿美元,针对常见的癌症亚型,副作用较少. Novartis to buy breast cancer drug SNV4818 from Synnovation for up to $3B, targeting a common cancer subtype with fewer side effects.

诺华公司已同意从Synnovation Therapeutics获得实验性乳腺癌药物SNV4818的价格高达30亿美元,其中20亿美元是预付款和10亿美元可能的里程碑. Novartis has agreed to acquire experimental breast cancer drug SNV4818 from Synnovation Therapeutics for up to $3 billion, with $2 billion paid upfront and up to $1 billion in potential milestones. 这种药物是一种选择性PI3Kα抑制剂,针对HR-阳性/ HER2-阴性的乳腺癌的特定突变,这是一个常见的亚型,目前正在临床试验中. The drug, a selective PI3Kα inhibitor, targets a specific mutation in HR-positive/HER2-negative breast cancer, a common subtype, and is in early clinical trials. 设计以保护健康组织, 其目的是减少与现有疗法相比的副作用. Designed to spare healthy tissue, it aims to reduce side effects compared to existing therapies. 这笔预计将于2026年初完成的交易加强了诺华公司的瘤管道,并支持其专注于精密医疗. The deal, expected to close in early 2026, strengthens Novartis’s oncology pipeline and supports its focus on precision medicine.